Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2025
Atomoxetine plus oxybutynin for symptomatic snoring and airflow limitation in individuals without moderate-to-severe obstructive sleep apnea.
СтатьяРандомизированное исследованиеПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Calianese Nicole, Hess Lauren B, Vena Daniel, Konefal Robert, Mann Dwayne L, Taranto-Montemurro Luigi, Bertisch Suzanne M, Sofer Tamar, Azarbarzin Ali, Gell Laura K, Sands Scott A
Аннотация
STUDY OBJECTIVES: Sleep-disordered breathing is incompletely characterized by the apnea-hypopnea index. Although typically viewed as milder disease, snoring and flow limitation can yield major deficits in sleep health for both patients and their bed partners. Here we tested whether a combined noradrenergic and antimuscarinic intervention to activate pharyngeal muscles yields improved snoring loudness and flow limitation severity, plus self-reported outcomes, by snorers and their bed partners.
METHODS: In a randomized placebo-controlled double-blind crossover study, adults with loud habitual snoring took atomoxetine plus oxybutynin for 10 days before bedtime at full adult doses (80 and 5 mg, respectively; half-dose run-in on days 1-3) and at half-doses (40 and 2.5 mg, respectively). Baseline polysomnography with tracheal sound recording established baseline snoring (mean loudness > 75 dB) and an apnea-hypopnea index of < 15 events/h. Mixed models compared full and half-doses to placebo in snoring loudness, flow limitation, and snoring self-evaluation and bed-partner evaluation scores, adjusting for baseline and period effects (intention-to-treat analysis).
RESULTS: Fifteen participants were randomly assigned and 13 completed all treatment periods. Snoring loudness was reduced with full dose (-9.3 [-19.6, -2.9] dB; difference [95% confidence interval]) and half-dose (-9.0 [-17.8, -3.2] dB) vs placebo (102.2 dB), equivalent to a two-thirds reduction in snoring amplitude. Flow-limitation severity was also meaningfully reduced (both doses). The Snoring Bed-Partner Evaluation Scale was reduced with the half-dose only (-2.8 [-5.3, -0.4] points from 10.1 on placebo). Self-evaluation scores were lowered exclusively in 7 of the 15 participants with bothersome snoring at baseline (treatment × subgroup interactions).
CONCLUSIONS: In patients with habitual snoring, atomoxetine plus oxybutynin at half- and full doses improves snoring and flow limitation. A half-dose may also improve bed-partner outcomes.
CLINICAL TRIAL REGISTRATION: Registry: ClinicalTrials.gov; Name: Pharmacological Intervention for Symptomatic Snoring; URL: https://clinicaltrials.gov/study/NCT03720353; Identifier: NCT03720353.
CITATION: Calianese N, Hess LB, Vena D, et al. Atomoxetine plus oxybutynin for symptomatic snoring and airflow limitation in individuals without moderate-to-severe obstructive sleep apnea. J Clin Sleep Med. 2025;21(9):1579-1590.
METHODS: In a randomized placebo-controlled double-blind crossover study, adults with loud habitual snoring took atomoxetine plus oxybutynin for 10 days before bedtime at full adult doses (80 and 5 mg, respectively; half-dose run-in on days 1-3) and at half-doses (40 and 2.5 mg, respectively). Baseline polysomnography with tracheal sound recording established baseline snoring (mean loudness > 75 dB) and an apnea-hypopnea index of < 15 events/h. Mixed models compared full and half-doses to placebo in snoring loudness, flow limitation, and snoring self-evaluation and bed-partner evaluation scores, adjusting for baseline and period effects (intention-to-treat analysis).
RESULTS: Fifteen participants were randomly assigned and 13 completed all treatment periods. Snoring loudness was reduced with full dose (-9.3 [-19.6, -2.9] dB; difference [95% confidence interval]) and half-dose (-9.0 [-17.8, -3.2] dB) vs placebo (102.2 dB), equivalent to a two-thirds reduction in snoring amplitude. Flow-limitation severity was also meaningfully reduced (both doses). The Snoring Bed-Partner Evaluation Scale was reduced with the half-dose only (-2.8 [-5.3, -0.4] points from 10.1 on placebo). Self-evaluation scores were lowered exclusively in 7 of the 15 participants with bothersome snoring at baseline (treatment × subgroup interactions).
CONCLUSIONS: In patients with habitual snoring, atomoxetine plus oxybutynin at half- and full doses improves snoring and flow limitation. A half-dose may also improve bed-partner outcomes.
CLINICAL TRIAL REGISTRATION: Registry: ClinicalTrials.gov; Name: Pharmacological Intervention for Symptomatic Snoring; URL: https://clinicaltrials.gov/study/NCT03720353; Identifier: NCT03720353.
CITATION: Calianese N, Hess LB, Vena D, et al. Atomoxetine plus oxybutynin for symptomatic snoring and airflow limitation in individuals without moderate-to-severe obstructive sleep apnea. J Clin Sleep Med. 2025;21(9):1579-1590.